Disclosures: Wajiha Khan: Nothing to Disclose, David Kim: Nothing to Disclose, Ariana Shari: Nothing to Disclose, Hamza Khan: Nothing to Disclose, Alexander Le: Nothing to Disclose, Christopher Hawryluk: Nothing to Disclose, Ivan Bobkov: Nothing to Disclose, Ahmed Al-Khazraji: Nothing to Disclose, Kaveh Hajifathalian: Nothing to Disclose 1083 IMPROVED LIVER FIBROSIS REGRESSION AFTER DIRECT-ACTING ANTIVIRAL THERAPY IN HEPATITIS C PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE Alexis McCary 1 Yi-shin Sheu 1 Karen Chesbrough 1 Cabell Jonas 1 , 1 Mid-Atlantic Permanente Medical Group Background: One third of the US population has some degree of liver steatosis, and many patients with Chronic Hepatitis C (CHC) meet criteria for metabolic dysfunction-associated steatotic liver disease (MASLD)

Key Specifications Telehealth with prescription : Yes Accepts insurance : No Consultation fee : No Membership fee : No Medications available : Compounded semaglutide or tirzepatide Pros and Cons Pros Doesnt require a membership
When you opt for a licensed treatment through a regulated provider, youre getting: A medication thats been through years of clinical trials to prove it actually works
We incorporate micro-incentives and gamified tracking throughout the user experience